Investor Presentation- 3Q2020 Disclaimer

 This presentation contains forward-looking statements, including, but not limited to, statements concerning expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, plans or goals relating to financial position and future operations and development. Although Saudi German Hospitals Group believes that the expectations and opinions reflected in such forward looking statements are reasonable, no assurance can be given that such expectations and opinions will prove to have been correct. By their nature, these forward- looking statements are subject to a number of known and unknown risks, uncertainties and contingencies, and actual results and events could differ materially from those currently being anticipated as reflected in such statements. Important factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements, certain of which are beyond our control, include, among other things: business integration risk; compliance risk; recruitment and retention of skilled medical practitioners risk: clinical risk; concentration of revenue; currency and macroeconomic; information technology and operational risk; regional tensions and political risk; and other key factors that we have indicated could adversely affect our business and financial performance, which are contained elsewhere in this document and in our past and future filings and reports. No part of these results constitutes, or shall be taken to constitute, an invitation or inducement to invest in Saudi German Hospital or any other entity and must not be relied upon in any way in connection with any investment decision. Saudi German Hospital undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required. Nothing in this document should be construed as a profit forecast.

2 TABLE OF CONTENTS

MEAHCO At a glance 1

Turnaround Revolution 2

Key Financial Indicators 3

Ambitious Expansion Strategy 4

Shareholders Information 5

Employees Statistics 6

3 Financials Snapshot 7 MEAHCO At A Glance

4 MEAHCO AT A GLANCE

’s most geographically diversified healthcare player.  Full fledged footprint in six cities (, Asser, , Madinah, Hail, ).  Comprehensive network covering ~90% of Saudi Arabia’s population.  Ongoing expansion into Makkah, along with Madinah, to capitalize on religious tourism and further expand reach.  Successful launch of Beverly Clinics to add new catchment areas in Jeddah. 5 Geographic Footprint

Asser Madinah Beverly Clinics Establishment 2000 Establishment 2003 Establishment 2018 400 Licensed Beds 300 Licensed Beds 20 Clinics 291 Operational Beds 197 Operational Beds 89 Clinics 58 Clinics

06 01 01 02 03 04 05 06 07

Jeddah Riyadh Hail Dammam Establishment 1988 Establishment 2001 Establishment 2017 Establishment 2020 217 Licensed Beds 300 Licensed Beds 150 Licensed Beds 150 Licensed Beds 204 Operational Beds 214 Operational Beds 90 Operational Beds 98 Operational Beds 131 Clinics 69 Clinics 24 Clinics 16 Clinics 6 Hospitals under management contract

➢SGH – est. 2006 ➢SGH Dubai – est. 2012 ➢SGH – est. 2015 ➢SGH – est. 2018 ➢SGH Ajman – est. 2019

Operational Pipeline ➢SGH Alex West () ➢SGH Giza (Egypt) ➢SGH Lahore () ➢SGH Islamabad (Pakistan) ➢SGH Karachi (Pakistan) ➢BTPL Lahore (Pakistan) ➢SGH Casablanca ()

7 Turnaround Revolution

8 Turnaround Revolution

Integration Digital Transformatio Diversification n Accreditation

Restructure Technology Patients Cost Satisfaction 9 Efficiency Accreditation

Jeddah Asser Riyadh Madinah Hail Dammam

Accredited Accredited Accredited Accredited In process In process

Accredited Accredited Accredited Accredited Accredited In process

In process In process In process In process In process In process

Accredited In process In process Accredited Accredited In process

In process In process In process In process In process In process

Note 10  SGH Management is planning to have all hospitals fully accredit by end of 2021. Key Financial Indicators

11 Key Financial Indicators

Revenue, Revenue growth EBITDA, EBITDA margin Net profit, Net profit margin

600 EBITDA EBITDA margin Net profit Net profit margin 492 500 100 15.7% 20% 36 8.6% 10% 387 16.1% 35 400 8% 80 15% 35 7.1% 300 60 34 6% 10% 200 40 34

SAR SAR million 4%

SAR SAR million 5% 33 100 20 SAR million 2% 33 0 0 0% 32 0% 3Q19 3Q20 3Q19 3Q20 3Q19 3Q20

1,302 1,400 EBITDA EBITDA margin Net profit Net profit margin 1,200 1,090 200 14.5% 15% 80 15% 1,000 13.3% 15% 12% 800 150 60 14% 9% 600 100 40 14% 6%

SAR SAR million 400 5.5% 5.6% SAR SAR million SAR SAR million 50 20 200 13% 3% 0 0 13% 0 0% 9M19 9M20 9M19 9M20 9M19 9M20

12 Operational KPIs

Number of performed surgeries Utilization rate Average length of stay

4.28 12,000 100.00% 5 4.08 4 10,000 80.00% 69.79% 70.03% 4 8,000 3 60.00% 3 6,000 Bed utilisation 2 40.00% 4,000 2 1

2,000 20.00% 7,936 10,277 1 0 0.00% 0 3Q19 3Q20 9M19 9M20 3Q19 3Q20

25,000 100% 5 4.25 4.09 4 24,000 80% 4 23,000 57% 3 60% 49% 3 22,000 Clinic utilisation 2 40% 21,000 2 1

20,000 20% 24,342 21,326 1 19,000 0% 0 9M19 9M20 9M19 9M20 9M19 9M20

13 Revenue structure

Revenue breakdown by service Revenue breakdown by clientele GPM breakdown by service

3Q19 3Q20 Insurance Ministry of Health Cash Others 3Q19 3Q20

350 301.7 100% 3% 2% 40% 35.9% 35.0% 33.0% 300 19% 21% 35% 31.7% 80% 250 30% 200 60% 29% 34% 25% 150 111.20 20%

100 76.4 40% 15% SAR SAR million 10% 50 3 20% 49% 43% 0 5% IP OP Pharmacy Trading & 0% 0% Ancillary 3Q19 3Q20 IP OP Pharmacy Total

9M19 9M20 Insurance Ministry of Health Cash Others 9M19 9M20

1,000 100% 4% 2% 40% 35.5% 804.16 32.6% 33.8% 18% 20% 800 80% 30% 26.1% 600 60% 29% 33% 400 279.9 20%

209.4 40% SAR SAR million 200 10% 9.6 20% 49% 45% 0 IP OP Pharmacy Trading & 0% 0% Ancillary 9M19 9M20 IP OP Pharmacy Total

14 Patients Evolution

Historical trends 3Q19 vs. 3Q20 9M19 vs. 9M20

Number of inpatients Number of inpatients Number of inpatients

60,000 25,000 21,681 60,000 51,763 50,000 50,000 20,000 40,737 40,000 14,923 40,000 15,000 30,000 30,000 10,000 20,000 20,000 10,000 5,000 10,000 0 0 0 2015 2016 2017 2018 2019 3Q19 3Q20 9M19 9M20

Number of outpatients Number of outpatients Number of outpatients

1,400,000 400,000 1,000,000 875,232 338,006 820,915 1,200,000 293,362 800,000 1,000,000 300,000 800,000 600,000 200,000 600,000 400,000 400,000 100,000 200,000 200,000 0 0 0 2015 2016 2017 2018 2019 3Q19 3Q20 9M19 9M20

15 Balance sheet and cash cycle

Cash conversion cycle Receivables, Receivables split Leverage

9M20 1,600 1,471 Net debt/Equity (x) 1,400 400 336 339 1.0 350 1,200 0.80 300 250 1,000 0.8 200 0.61 150 107 110 800 0.6 100 50 600

SAR SAR million 0.4 0 400 0.2 200

Days Days Hand on (DoH) 0 0.0 9M20 FY19 9M20

9M19 Ministry of Health Insurance Others Related Party Net debt/EBITDA (x) 324 350 2% 6.0 279 11% 5.17 300 4.69 250 5.0 200 153 150 108 4.0 100 9M20 3.0 50 0 31% 56% 2.0 1.0

Days Days Hand on (DoH) 0.0 FY19 9M20

16 Ambitious Expansion Strategy

17 Expansion and CAPEX

Jeddah Maternity & Child Riyadh Outpatient Tower Makkah Housing Hospital 134 beds,160 clinics Capex 114 million Capex 194 million To be operational 35 beds,16 clinics. To be operational 4Q 2021 Rent SAR 7 m in 2 years 2Q 2021 2Q 2021 Makkah Hospital Dammam Housing 300 beds Capex 90 million Capex 389 million To be operational To be operational 4Q 2021 18 3Q 2021 Shareholders Information

19 Shareholders Information

Sharholder Structure SGH versus TASI Performance

17.2% 19.0%

7.1% 7.8%

13.0%

54.7%

Foreign Retail Local Institutions Foreign Institutions Bait Al-Batterjee IFC Local Retail

20 Employees statistics

Headcount split by profession Number of employees Saudization rate

Doctors Nurses Allied Health Admin Staff 6,000 5,618 Saudi Non-Saudi 5,339

15% 5,000

4,000 34%

44% 3,000

2,000 29%

1,000 66%

9M20 0 9M20 12% 9M19 9M20

21 Board of Directors

Non-Executive Board Members Group Chairman SeniorIndependent Executives Board BoardMembersMembers

Mr. Makarem Batterjee Mr. Khaled Batterjee Mr. Amr Khashoggi Mr. Mohamed Moumena Board Member Board Member Board Member Board Member Mr. Sobhi Batterjee Chairman

Mr. Sultan Batterjee Mr. Mohamed Bin Siddiq Board Member Board Member

22 Financials Snapshot

23 Income Statement Snapshot

All figures in SAR ،000 30-Sep-20 30-Sep-19 Revenue 492,132 386,756 Cost of revenue -320,226 -266,796 Gross Profit 171,906 119,960 Selling and Marketing expenses -10,108 -4,096 General and Admin. expenses -119,679 -82,554 Operating Profit 43,291 37,204 other income 1,173 3,895 Finance cost -7,820 -6,059 Profit before Zakat 35,471 31,145 Zakat -1,500 -1,500 Net Profit of the period 33,971 29,645

24 Balance Sheet Snapshot

All figures in SAR ،000 30-Sep-20 31-Dec-19

Total Non Current Assets 2,029,185 1,944,838

Inventories 142,913 124,514

Accounts Receivable 1,471,133 1,108,576

Total Current Assets 1,715,048 1,360,659

Total Assets 3,744,233 3,305,497

Total Non Current Liabilities 966,695 923,080

Total Current Liabilities 1,150,064 820,603

Shareholders' Equity 1,627,475 1,561,814

Total Equity and Liabilities 3,744,233 3,305,497

25 Stock Data: Bloomberg / Reuters: MEH AB / 4009.SE Outstanding shares: 92,040,000 Free float: 38.2% Mkt. Cap: USD 895 million 3M ADVT: USD 7.1 million

Investor Relations contacts: Tamer Nigm Madani Hozaien Director-Strategic Planning & IR Group CFO M: +966 55 269 5722 E:[email protected] E: [email protected]

26 Thank you